• DISCOVERING ADVANCE THERAPIES FOR A NEW WORLD

    We are creating centers of excellence in dermatology, oncology and respiratory therapy. The effort is to develop advance therapies to enrich the lives of patients worldwide.

  • A NEW WORLD. A HEALTHIER WORLD.

    With offices in over 50 countries, 14 manufacturing facilities in four countries and 3 R&D centres worldwide, we work relentlessly towards improving the quality of life of patients across the globe.

  • A NEW WAY FOR A NEW WORLD

    At King, we believe in enriching lives and making a difference to patients all over the world. We constantly strive to find new ways that pave the way for a healthier tomorrow.

TRANSFORMING SCIENCE INTO SMILES

R & D is at the heart of King’ success. A highly qualified team works round the clock with a quest to develop a progressive threefold product basket that includes world-class generics, oncology and parenteral as well as added-value products (AVPs).

  • 6-7% of turnover invested in R & D, year on year
  • Over 1,00,000 sq ft dedicated R&D space
  • 550+ Scientists and Researchers
  • 16 Advanced Facilities
  • Global Regulatory Authority Accreditations
  • Pioneer in Biosimilars
Formulations
1 +
Brands
1 +
API's
1 +
Countries
1 +

Ensuring health for all

King's formulation business has emerged as most competitive in the evolving generic space with a core focus on vertical integration. We have a diverse product portfolio catering to major therapeutic segments in virtually every dosage form – Oral solids, Powder for suspension and Small volume injections (dry & liquid). Having established the essence and resolve to compete in the growing generic arena we have fortified our capabilities in terms of infrastructure with 4 dedicated manufacturing facilities catering to regulated markets, having accreditation from Health Canada, Government of Oberfranken-Germany, Halmed-Croatia, MHRA-UK, TGA-Australia, SAHPRA-South Africa, and WHO-Geneva. Our state of the art facilities are designed with an eye on addressing the economies of scale offering a competitive edge.

A vertically-integrated player with strengths across the pharmaceutical value chain

OUR DIVISIONS

As a research-based pharmaceutical company, King’ Innovation programme is spearheaded by 1100 researchers across 17 sites, working on differentiated medicines for the future. From NCEs to vaccines, biosimilars and niche technologies, the group is exploring different ideas, concepts and continuously innovating.

ENVIRONMENT, HEALTH AND SAFETY (EHS) POLICY

STATE-OF-THE-ART MANUFACTURING CAPABILITIES

 King is fully committed to and continuously endeavors to achieve environment, health and safety excellence across all the units. The Company continues to invest substantial resources towards sustaining and continuously improving the standards of environment, occupational health and safety as it believes that its responsibility towards the society and the environment extends beyond those laid down by the regulatory authorities.

© 2021, KING LABORATORIES PVT. LTD.
King Laboratories Pvt. Ltd.